The Israel-based startup now has $50 million in funding to expand its solutions and clinical research as well as support global implementation of its solutions.
Medial EarlySign’s technologies include AI- and machine learning-based clinical decision support solutions for healthcare providers and laboratories as well as custom solutions targeted toward disease-specific patient management. Its solutions are being tested in clinical data studies involving 20 million-plus patients, according to the report.
More articles on artificial intelligence:
